Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: September 13, 2012
Last updated: April 21, 2017
Last verified: April 2017
This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study. At each clinic visit, adverse events will be assessed and exacerbations will also be reviewed.

Condition Intervention Phase
Drug: Mepolizumab
Phase 3

Access to an investigational treatment associated with this study is available outside the clinical trial.   More info ...

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Frequency of all Adverse Events [ Time Frame: 48 months ]
    Frequency of all Adverse Events

Secondary Outcome Measures:
  • ECG parameters [ Time Frame: 48 months ]
    ECG parameters as measured by mean change and maximum change from baseline in QTcF and QT

  • Clinical laboratory tests [ Time Frame: 48 months ]
    Clinical laboratory tests as measured by abnormal parameters for hematology and clinical chemistry

  • Vital Signs [ Time Frame: 48 months ]
    Vital signs as measured by change in pulse and BP from baseline

  • Annualized rate of exacerbation [ Time Frame: 48 months ]
    Annualized rate of exacerbation

  • Quality of Life (QOL) [ Time Frame: 48 months ]
    QOL as measured by Asthma Control Questionnaire score (ACQ)-5

  • Lung Function [ Time Frame: 48 months ]
    Lung function as measured by changes from baseline in Forced vital capacity (FVC) and Forced expiratory volume in 1 second (FEV1) measured by clinic spirometry

  • Immunogenecity [ Time Frame: 48 months ]
    Immunogenecity as measured by positive neutralizing antibody

  • Number of participant withdrawals [ Time Frame: 48 months ]
    Number of participant withdrawals due to lack of efficacy or due to adverse events were summarized

  • Number of hospitalizations due to adverse events including asthma exacerbations [ Time Frame: 48 months ]
    Number of hospitalizations due to adverse events including asthma exacerbations

  • Frequency of immune reactions [ Time Frame: 48 months ]
    Frequency of immune reactions

Estimated Enrollment: 150
Actual Study Start Date: September 28, 2012
Estimated Study Completion Date: May 30, 2017
Estimated Primary Completion Date: May 30, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mepolizumab
Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
Drug: Mepolizumab
100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Informed Consent.
  • MEA112997 Study Participation: Received at least 2 doses of double-blind investigational product during the MEA112997 trial.
  • MEA112997 Treatment Assignment: If the subject received mepolizumab, they must have had a positive risk: benefit ratio.
  • Currently being treated with a controller medication and the subject has been on a controller medication for the past 12 weeks.
  • Male or Eligible Female Subjects. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration.

Exclusion Criteria:

  • Hypersensitivity related to mepolizumab.
  • Clinically significant change in health status since completing participation in the MEA112997 trial.
  • A current malignancy or previous history of cancer in remission for less than 12 months prior to screening.
  • For those subjects who had a SAE in MEA112997 that was assessed as possibly related to mepolizumab by the investigator.
  • Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.
  • Screening ECG which has a clinically significant abnormality.
  • Received Xolair (omalizumab) within the past 130 days.
  • Participated in a clinical trial within the past 30 days or have received investigational medication within five terminal half-lives of Screen Visit, whichever is longer.
  • Current smokers.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01691859

  Show 67 Study Locations
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT01691859     History of Changes
Other Study ID Numbers: 115666
Study First Received: September 13, 2012
Last Updated: April 21, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by GlaxoSmithKline:
extension study
Severe refractory asthma
eosinophils processed this record on April 27, 2017